US2005197309A1PendingUtilityA1
Antisense modulation of dual specific phosphatase 5 expression
Priority: Aug 14, 1990Filed: Jan 14, 2005Published: Sep 8, 2005
Est. expiryAug 14, 2010(expired)· nominal 20-yr term from priority
Inventors:C. Frank BennettBrett P. MoniaSusan M. FreierChristopher K. MirabelliIan PopoffJacqueline WyattAndrew WattKenneth Dobie
C12N 15/1137C12Y 301/03016C12N 2310/315C12Y 301/03C07H 21/04C12N 2310/3341C12N 2310/3521C12Y 301/03048C12N 2310/321C12N 2310/346C12N 2310/11A61K 38/00C12N 2310/341Y02P20/582
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of dual specific phosphatase 5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding dual specific phosphatase 5. Methods of using these compounds for modulation of dual specific phosphatase 5 expression and for treatment of diseases associated with expression of dual specific phosphatase 5 are provided.
Claims
exact text as granted — not AI-modified1 . A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding dual specific phosphatase 5, wherein said compound specifically hybridizes with and inhibits the expression of dual specific phosphatase 5.
2 . The compound of claim 1 which is an antisense oligonucleotide.
3 . The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 25, 29, 32, 36, 37, 38, 40, 41, 42, 45, 50, 51, 52, 53, 56, 57, 61, 63, 64, 65, 66, 68, 71, 72, 73, 74, 75, 77, 79, 80, 81, 83, 84, 85, 87 or 88.
4 . The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5 . The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6 . The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7 . The compound of claim 6 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.
8 . The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9 . The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
10 . The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
11 . A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding dual specific phosphatase 5.
12 . A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
13 . The composition of claim 12 further comprising a colloidal dispersion system.
14 . The composition of claim 12 wherein the compound is an antisense oligonucleotide.
15 . A method of inhibiting the expression of dual specific phosphatase 5 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of dual specific phosphatase 5 is inhibited.
16 . A method of treating an animal having a disease or condition associated with dual specific phosphatase 5 comprising administering to said animal a-therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of dual specific phosphatase 5 is inhibited.
17 . The method of claim 16 wherein the disease or condition is a hyperproliferative disorder.
18 . The method of claim 16 wherein the disease or condition is a developmental disorder.
19 . The method of claim 16 wherein the disease or condition an inflammatory disease.
20 . The method of claim 16 wherein the disease or condition arises from aberrant apoptosis.Join the waitlist — get patent alerts
Track US2005197309A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.